HHCP
DYN icon

Hilton Head Capital Partners’s Dyne Therapeutics DYN Stock Holding History

Hilton Head Capital Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76K Buy
3,420
+1,974
+137% +$36.7K 0.04% 248
2026
Q1 		$26.2K Buy
+1,446
New +$24.9K 0.01% 417

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Hilton Head Capital Partners's DYN Position: Q2 2026 in Review

Hilton Head Capital Partners increased its Dyne Therapeutics (DYN) stake by 137% in Q2 2026, buying an estimated $36.7K and bringing the position to 3,420 shares worth $76K. The position accounts for 0.04% of the portfolio, ranked #248.

Hilton Head Capital Partners first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Hilton Head Capital Partners held 3,420 shares of Dyne Therapeutics worth $76K as of Q2 2026.
  • Hilton Head Capital Partners bought 1,974 Dyne Therapeutics shares in Q2 2026, an estimated $36.7K.
  • Dyne Therapeutics made up 0.04% of Hilton Head Capital Partners's portfolio in Q2 2026, its #248 holding.
  • Hilton Head Capital Partners first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.